Liver cancer has a very high prevalence among cancers in general and is one of the most common causes of death worldwide. Based on these facts, the journal ‘Liver Cancer’ serves the growing need to better understand the causes, mechanisms and therapy of the malignancy. It provides the international community of researchers and clinicians with a platform for their research results, focusing on molecular carcinogenesis, prevention, surveillance, diagnosis and treatment, including molecular targeted therapy, of the disease. 'Liver Cancer' publishes clinical and translational research related to the field of liver cancer in both humans and experimental models in the form of original and review articles.
肝癌在一般癌症中具有非常高的患病率，并且是全球最常见的死亡原因之一。基于这些事实，《肝癌》杂志为更好地了解恶性肿瘤的原因、机制和治疗提供了越来越多的需求。它为国际社会的研究人员和临床医生提供了一个平台，展示他们的研究成果，重点是该疾病的分子致癌作用、预防、监测、诊断和治疗，包括分子靶向治疗。《肝癌》以原创和综述文章的形式发表与人类和实验模型肝癌领域相关的临床和转化研究。
Systemic Treatment Options in Hepatocellular Carcinoma
来源期刊：Liver CancerDOI：10.1159/000499765
Systemic Treatment for Advanced Hepatocellular Carcinoma
来源期刊：Liver CancerDOI：10.1159/000496439
Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma
来源期刊：Liver CancerDOI：10.1159/000496277
A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE
来源期刊：Liver CancerDOI：10.1159/000502905
B-Mode Ultrasonography versus Contrast-Enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled Trial
来源期刊：Liver CancerDOI：10.1159/000501082
Pembrolizumab for the Treatment of Hepatocellular Carcinoma
来源期刊：Liver CancerDOI：10.1159/000500143
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
来源期刊：Liver CancerDOI：10.1159/000501275
Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients
来源期刊：Liver CancerDOI：10.1159/000502744
Sorafenib: Experience and Better Management of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis
来源期刊：Liver CancerDOI：10.1159/000497161
Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition)
来源期刊：Liver CancerDOI：10.1159/000503685
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma
来源期刊：Liver CancerDOI：10.1159/000504624
Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib
来源期刊：Liver CancerDOI：10.1159/000504604
18F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib
来源期刊：Liver CancerDOI：10.1159/000503577
Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib
来源期刊：Liver CancerDOI：10.1159/000503031
Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions
来源期刊：Liver CancerDOI：10.1159/000494843
Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies
来源期刊：Liver CancerDOI：10.1159/000502479
Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies
来源期刊：Liver CancerDOI：10.1159/000503254
Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review
来源期刊：Liver CancerDOI：10.1159/000503719
Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma
来源期刊：Liver CancerDOI：10.1159/000497460
Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan
来源期刊：Liver CancerDOI：10.1159/000495944
Management of Hepatocellular Carcinoma in Japan: Current Trends
来源期刊：Liver CancerDOI：10.1159/000505370
Comprehensive Consideration before the Decision-Making of the Systemic Treatment in Patients with Advanced Hepatocellular Carcinoma
来源期刊：Liver CancerDOI：10.1159/000502775
Assessment of Preoperative Liver Function for Surgical Decision Making in Patients with Hepatocellular Carcinoma
来源期刊：Liver CancerDOI：10.1159/000501368
Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial
来源期刊：Liver CancerDOI：10.1159/000503032
Waist Circumference and Risk of Liver Cancer: A Systematic Review and Meta-Analysis of over 2 Million Cohort Study Participants
来源期刊：Liver CancerDOI：10.1159/000502478
Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma
来源期刊：Liver CancerDOI：10.1159/000504252
Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients
来源期刊：Liver CancerDOI：10.1159/000503829
Microvascular Invasion and a Size Cutoff Value of 2 cm Predict Long-Term Oncological Outcome in Multiple Hepatocellular Carcinoma: Reappraisal of the American Joint Committee on Cancer Staging System and Validation Using the Surveillance, Epidemiology, and End-Results Database
来源期刊：Liver CancerDOI：10.1159/000504193
Hepatic Artery Embolization Induces the Local Overexpression of Transforming Growth Factor β1 in a Rat Hepatoma Model
来源期刊：Liver CancerDOI：10.1159/000502774
Too Many versus Too Few Platelets in Patients with Hepatocellular Carcinoma: Good or Bad?
来源期刊：Liver CancerDOI：10.1159/000503391
Mean Platelet Volume and Unresectable Hepatocellular Carcinoma
来源期刊：Liver CancerDOI：10.1159/000502480
Synthetic Lethality Is a Novel and Potential Paradigm for Precision Medicine in Advanced Hepatocellular Carcinoma
来源期刊：Liver CancerDOI：10.1159/000503927
Response to the Comments on Rimassa et al.: “Systemic Treatment Options in Hepatocellular Carcinoma”
来源期刊：Liver CancerDOI：10.1159/000503302
NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization
来源期刊：Liver CancerDOI：10.1159/000501484
Liver Transplant for Patients with Hepatocellular Carcinoma and Child-Pugh C Liver Function Should Be Mentioned in Guidelines
来源期刊：Liver CancerDOI：10.1159/000497459
Reply to the Letter to the Editor Entitled “Too Many versus Too Few Platelets in Patients with Hepatocellular Carcinoma: Good or Bad?”
来源期刊：Liver CancerDOI：10.1159/000504301
Irradiation-Related Lymphopenia for Bone Metastasis from Hepatocellular Carcinoma
来源期刊：Liver CancerDOI：10.1159/000500461
Intracranial Bleeding during Treatment with Sorafenib for Hepatocellular Carcinoma
来源期刊：Liver CancerDOI：10.1159/000496546
Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand
来源期刊：Liver CancerDOI：10.1159/000501485
Response to the Letter to the Editor Concerning the Publication “Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma”
来源期刊：Liver CancerDOI：10.1159/000502745
Contents Vol. 8, 2019
来源期刊：Liver CancerDOI：10.1159/000504073
